Gastrointestinal Cancers Symposium (ASCO GI) | Conference

Dr. Abou-Alfa on LY2157299 in HCC

January 28th 2014

Ghassan K. Abou-Alfa, MD, discusses the phase II study of a novel transforming growth factor-beta (TGF-Î²1) receptor I kinase inhibitor, LY2157299 monohydrate, in patients with advanced hepatocellular carcinoma (HCC), which was presented at the 2014 Gastrointestinal Cancers Symposium.

Dr. Bordonaro on First-Line Treatment Options for mCRC

January 24th 2014

Roberto Bordonaro, MD, discusses first-line treatment options for advanced colorectal cancer (CRC).

Dr. Fakih on RAS Mutations in Colon Cancer

January 22nd 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses extended RAS mutations in colon cancer.

RAS Mutational Analyses in mCRC Trials Highlight Need to 'Think Beyond KRAS'

January 20th 2014

Studies presented at the 2014 GI Cancers Symposium emphasized the need for full RAS mutational analyses in the management of metastatic colorectal cancer prior to initiating treatment with anti-EGFR monoclonal antibodies.

Novel Targeted Agent Leads to Survival Benefit in HCC

January 20th 2014

Treatment with LY2157299 led to significant reductions in a prespecified biomarker that correlated with increased time to progression and overall survival in patients with advanced hepatocellular carcinoma.

Hedgehog Inhibitor Regimen Active in Advanced Pancreatic Cancer

January 20th 2014

Add-on treatment with the hedgehog pathway inhibitor vismodegib demonstrated encouraging activity in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Dr. Ramanathan on Biomarkers in Appendix Cancer

January 20th 2014

Ramesh K. Ramanathan, MD, discusses the potential of identifying actionable targets in appendiceal cancers.

Dr. John Marshall Provides Colorectal Cancer Updates

January 17th 2014

John L. Marshall, MD, from Georgetown University Hospital, on the recent advancements in colorectal cancer.

Dr. Fine on Capecitabine Plus Temozolomide for NETs

January 17th 2014

Robert L. Fine, MD, from the Columbia University Medical Center, discusses the prospective phase II study of CAPTEM for patients with neuroendocrine tumors.

Dr. Smitha Krishnamurthi on the Phase III RAINBOW Trial

January 17th 2014

Smitha Krishnamurthi, MD, discusses the results of the RAINBOW TRIAL

High Response Rates Observed With CAPTEM in Chemo-Resistant Neuroendocrine Tumors

January 14th 2014

Data from an interim analysis of an ongoing phase II study suggest that patients with carcinoid and pituitary NETs, who have been traditionally chemo-resistant, may obtain "extraordinary responses" with capecitabine and temozolomide.

Neoadjuvant Capecitabine Considered a New Standard of Care in Rectal Cancer

January 14th 2014

Single-agent neoadjuvant capecitabine combined with radiation therapy demonstrated similar outcomes as previously established standards of care for patients with stage II or stage III rectal cancer.

Ramucirumab Combination Improves Survival in Metastatic Gastric Cancer

January 14th 2014

The combination of ramucirumab and paclitaxel resulted in a significant prolongation in survival and gains in quality of life when compared to paclitaxel alone for the second-line treatment of patients with metastatic gastric cancer.

Combined Vaccines Improve Survival in Metastatic Pancreatic Cancer

January 14th 2014

Combining two specific anti-cancer vaccines, rather than administering one as monotherapy, doubles the 1-year survival probability in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), according to the results of a phase II study presented January 14.

Second-Line mCRC Data Further Support RAS Testing Before Panitumumab Use

January 14th 2014

An analysis of phase III, second-line data has shown that RAS mutations beyond KRAS exon 2 are negative predictive biomarkers for the EGFR-inhibitor panitumumab in metastatic colorectal cancer.

Side Effects With Regorafenib Occur Early and Tend to Taper

March 8th 2013

The incidence of adverse effects with regorafenib in metastatic colorectal cancer is highest during the first treatment cycle and then diminishes over time.

Similar Benefit, Lower Toxicity Found With Capecitabine- Versus Gemcitabine-based Chemoradiation in Pancreatic Cancer

March 6th 2013

Capecitabine produces similar local disease control with lower toxicity versus gemcitabine when combined with radiotherapy following induction chemotherapy in patients with locally advanced pancreatic cancer.

Bevacizumab Plus FOLFOXIRI May Offer New First-Line Option in mCRC

March 5th 2013

FOLFOXIRI plus bevacizumab improved progression-free survival and response rates with a modest increase in side effects compared with FOLFIRI plus bevacizumab in patients with unresectable metastatic colorectal cancer.

Complete Neoadjuvant Chemotherapy May Offer New Framework for Treating Rectal Cancer

March 4th 2013

Complete neoadjuvant treatment may represent a well-tolerated alternative to the current standard treatment sequence of adjuvant chemotherapy following chemoradiation and surgery.

Dr. Yao on Everolimus in Advanced Pancreatic NET

February 5th 2013

James C. Yao, MD, from the MD Anderson Cancer Center, describes the administration of the mTOR inhibitor everolimus in patients with pancreatic neuroendocrine tumors.